FDA Clearance Tracker · P050052-S162
RADIESSE® Injectable Implant
Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 31, 2026
Approved
Time to decision
678 days
Received May 22, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P050052-S162
- Device name
- RADIESSE® Injectable Implant
- Applicant
- Merz North America, Inc.
- Applicant location
- Franksville, WI
- Received
- May 22, 2024
- Decided
- Mar 31, 2026
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P050052
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for expanding the indications of Radiesse Injectable Implant diluted 1:2 with 0.9% sterile saline solution for subdermal implantation for the correction of décolleté wrinkles in patients 22 years of age and older.
Source documents
Other decisions for Merz North America, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250016 · Decided Jul 9, 2026 · 387 days after receipt
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.